BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts

• Published in: Circulation (New York, N.Y.) Vol. 114; no. 18; pp. 1962 - 1967
• Main Authors: Mullen, Michael J, Hildick-Smith, David, De Giovanni, Joseph V, Duke, Christopher, Hillis, W Stewart, Morrison, W Lindsay, Jux, Christian
• Format: Journal Article
• Language: English
• Published: United States 31.10.2006
• Subjects: Absorbable Implants; Adult; Aged; Echocardiography; Feasibility Studies; Female; Heart Septal Defects, Atrial - diagnosis; Heart Septal Defects, Atrial - diagnostic imaging; Heart Septal Defects, Atrial - surgery; Humans; Male; Middle Aged; Pilot Projects
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/CIRCULATIONAHA.106.664672

The use of permanent synthetic implants to close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations, including late complications and the limiting of transeptal access to the left heart should it be required for the later treatment of acquired heart disease. BioSTAR is a novel, bioabsorbable, atrial septal repair implant. This phase I pilot study evaluates the feasibility, safety, and effectiveness of BioSTAR for the first time in humans. We conducted a prospective, open-label, multicenter clinical study in 58 patients aged 28 to 68 years who had a clinically significant ASD or PFO. Percutaneous shunt closure was undertaken with the BioSTAR septal repair implant. Successful device implantation was achieved in 57 (98%) of 58 patients. Closure at 30 days and 6 months, assessed by contrast transthoracic echocardiography, was 48 (92%) of 52 and 54 (96%) of 56, respectively. There was no evidence of a clinically significant response to the device. Transient atrial arrhythmia occurred in 5 patients after implantation. No major safety issues were observed. This study demonstrates the feasibility, safety, and effectiveness of BioSTAR for the closure of ASD and PFO in humans with a high rate of early and complete shunt closure. BioSTAR is a novel septal repair implant designed to provide biological closure of atrial-level defects using the patient's natural healing response. Because 90% to 95% of the implant is absorbed and replaced with healthy native tissue, future access to the left atrium may be achieved.